Rhabdomyolysis would be rhabdomyolysis, and the probability of ezetimibe causing rhabdomyolysis is less than 10%. Adverse reactions of ezetimibe after marketing are allergic reaction, urticaria, rash, arthralgia, myalgia, rhabdomyolysis, hepatitis, abdominal pain, pancreatitis, cholelithiasis, thrombocytopenia, dizziness, headache, frustration, sensory abnormality, myopathy, erythema multiforme, hepatic transaminase elevation, etc. The probability of developing rhabdomyolysis by taking Ezetimibe is low, less than 10 percent. Ezetimibe is mainly used for the prevention of acute coronary syndromes, cardiovascular system diseases, and the treatment of familial hypercholesterolemia-pure, mixed hyperlipidemia, primary hypercholesterolemia, and pure familial glutathionemia. It is contraindicated in pregnant women, patients suspected to be pregnant, lactating women, patients allergic to the product, patients with active liver disease or unexplained persistent elevation of hepatic transaminase levels can not use the product together with statins. It is recommended that patients who are not feeling well should go to a regular hospital in time and follow the doctor’s instructions for symptomatic treatment.